分子影像技术应用于眼科肿瘤的研究进展

王玲; 朱雪; 王柯

doi:10.12122/j.issn.1674-4500.2023.06.32

分子影像技术应用于眼科肿瘤的研究进展

doi: 10.12122/j.issn.1674-4500.2023.06.32

王玲^{1, 2,},
朱雪^{1, 2},
王柯^{1, 2, ,}

1.
南京医科大学药学院核药学系，江苏南京 211166
2.
国家卫生健康委员会核医学重点实验室，江苏省分子核医学重点实验室，江苏省原子医学研究所，江苏无锡 214063

基金项目:

江苏省中医药科技发展计划项目 MS2022145

江苏省老年健康科研项目 2022043

江苏省科学技术厅社会发展项目 BE2022699

详细信息

作者简介:
王玲，在读硕士研究生，E-mail: lingwang@stu.njmu.edu.cn

通讯作者:
王柯，博士，研究员，E-mail: wangke@jsinm.org

计量
- 文章访问数: 114
- HTML全文浏览量: 54
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2023-08-10
- 网络出版日期: 2023-12-26
- 刊出日期: 2023-11-20

Research progress of molecular imaging technology for ocular tumor

WANG Ling^{1, 2
,},
ZHU Xue^{1, 2},
WANG Ke^{1, 2
, ,}

1.
Department of RadioPharmaceuticais, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China
2.
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China

摘要

摘要: 分子影像技术是一种采用非入侵性方式在活体状态下对生物体内的细胞或亚细胞行可视化和量化分析的技术，目前主要应用于疾病的早期诊断、分期、预后和个性化治疗。眼科肿瘤是一类可致死、致盲、致残的重要眼科疾病，本文基于眼部原发性恶性肿瘤的疾病分类、临床表现及治疗现状，对分子影像技术应用于眼科肿瘤诊断的研究进展进行综述。
- 分子影像技术 /
- 正电子发射型计算机断层显像 /
- 眼科肿瘤 /
- 葡萄膜黑色素瘤 /
- 眼附属器淋巴瘤 /
- 视网膜母细胞瘤
Abstract: Molecular imaging is a non-invasive technique for visualization and quantitative analysis of cells or subcells in vivo. At present, molecular imaging is mainly used for early diagnosis, staging, prognosis and personalized treatment of diseases. Ophthalmic tumors are a kind of important ophthalmic diseases which can cause death, blindness and disability. Based on the disease classification, clinical manifestations and treatment status of primary ocular malignant tumors, this paper reviews the research progress of molecular imaging technology in the diagnosis of ophthalmic tumors.
- molecular imaging /
- positron emission tomography /
- ocular tumor /
- uveal melanoma /
- ocular adnexal lymphoma /
- retinoblastoma

HTML全文

参考文献(56)

[1]	Williams BK, Di Nicola M. Ocular oncology-primary and metastatic malignancies[J]. Med Clin N Am, 2021, 105(3): 531-50. doi: 10.1016/j.mcna.2021.02.005
[2]	Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions[J]. CA Cancer J Clin, 2022, 72(4): 333-52. doi: 10.3322/caac.21713
[3]	Blum ES, Yang J, Komatsubara KM, et al. Clinical management of uveal and conjunctival melanoma[J]. Oncol Williston Park, 2016, 30(1): 29-32, 34-43, 48.
[4]	Smit KN, Jager MJ, de Klein A, et al. Uveal melanoma: towards a molecular understanding[J]. Prog Retin Eye Res, 2020, 75: 100800. doi: 10.1016/j.preteyeres.2019.100800
[5]	Krohn J, Sundal KV, Frøystein T. Topography and clinical features of iris melanoma[J]. BMC Ophthalmol, 2022, 22(1): 6. doi: 10.1186/s12886-021-02236-3
[6]	Simpson ER. Ciliary body melanoma: a special challenge[J]. Can J Ophthalmol, 2004, 39(4): 365-71. doi: 10.1016/S0008-4182(04)80007-3
[7]	Soliman N, Mamdouh D, Elkordi A. Choroidal melanoma: a mini review[J]. Medicines, 2023, 10(1): 11. doi: 10.3390/medicines10010011
[8]	Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma[J]. Nat Rev Dis Primers, 2020, 6(1): 24. doi: 10.1038/s41572-020-0158-0
[9]	Niendorf T, Beenakker JW M, Langner S, et al. Ophthalmic magnetic resonance imaging: where are we (heading to)?[J]. Curr Eye Res, 2021, 46(9): 1251-70. doi: 10.1080/02713683.2021.1874021
[10]	Kaštelan S, Gverović Antunica A, Beketić Orešković L, et al. Conjunctival melanoma-epidemiological trends and features[J]. Pathol Oncol Res, 2018, 24(4): 787-96. doi: 10.1007/s12253-018-0419-3
[11]	Koç İ, Kıratlı H. Current management of conjunctival melanoma part 2: treatment and future directions[J]. Turk J Ophthalmol, 2020, 50(6): 362-70. doi: 10.4274/tjo.galenos.2020.22567
[12]	Cohen VML, O'Day RF. Management issues in conjunctival tumours: conjunctival melanoma and primary acquired melanosis[J]. Ophthalmol Ther, 2019, 8(4): 501-10. doi: 10.1007/s40123-019-00219-8
[13]	Cid-Bertomeu P, Huerva V. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma[J]. Surv Ophthalmol, 2022, 67(5): 1391-404. doi: 10.1016/j.survophthal.2022.03.003
[14]	Scholz SL, Hérault J, Stang A, et al. Proton radiotherapy in advanced malignant melanoma of the conjunctiva[J]. Graefes Arch Clin Exp Ophthalmol, 2019, 257(6): 1309-18. doi: 10.1007/s00417-019-04286-2
[15]	Sa HS, Daniel C, Esmaeli B. Update on immune checkpoint inhibitors for conjunctival melanoma[J]. J Ophthalmic Vis Res, 2022, 17(3): 405-12.
[16]	Olsen TG, Heegaard S. Orbital lymphoma[J]. Surv Ophthalmol, 2019, 64(1): 45-66. doi: 10.1016/j.survophthal.2018.08.002
[17]	Chung HU, Son JH. Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review[J]. J Yeungnam Med Sci, 2022, 39(1): 3-11. doi: 10.12701/yujm.2021.01263
[18]	Tanenbaum RE, Galor A, Dubovy SR, et al. Classification, diagnosis, and management of conjunctival lymphoma[J]. Eye Vis, 2019, 6(1): 1-16. doi: 10.1186/s40662-018-0127-9
[19]	Demirci H, Ozgonul C, Diniz Grisolia AB, et al. Intralesional rituximab injection for low-grade conjunctival lymphoma management[J]. Ophthalmology, 2020, 127(9): 1270-3. doi: 10.1016/j.ophtha.2020.03.014
[20]	Dimaras H, Corson TW. Retinoblastoma, the visible CNS tumor: a review[J]. J Neurosci Res, 2019, 97(1): 29-44. doi: 10.1002/jnr.24213
[21]	Goncalves LF, Ramasubramanian A, Grebe T, et al. Prenatal diagnosis of bilateral retinoblastomas by multimodality fetal imaging: case report and review of the literature[J]. Clin Imag, 2021, 78: 121-6. doi: 10.1016/j.clinimag.2021.03.023
[22]	Schefler AC, Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma[J]. Fac Rev, 2021, 10: 51.
[23]	Kiernan M, Fabian I, Smith V, et al. Strabismus as a presenting sign in retinoblastoma[J]. J Pediatr Ophthalmol Strabismus, 2021, 58(5): 324-30. doi: 10.3928/01913913-20210614-03
[24]	Manrique M, Akinbolue D, Madigan WP, et al. Update on the treatment of retinoblastoma[J]. NeoReviews, 2021, 22(7): e423-37. doi: 10.1542/neo.22-7-e423
[25]	Chronopoulos A, Babst N, Schiemenz C, et al. A narrative review-therapy options and therapy failure in retinoblastoma[J]. Neurosignals, 2022, 30(S1): 39-58. doi: 10.33594/000000585
[26]	Su GL, Lim LA S, Welch RJ, et al. Retinoblastoma regression following intra-arterial chemotherapy to the contralateral eye[J]. Saudi J Ophthalmol, 2019, 33(3): 291-3. doi: 10.1016/j.sjopt.2019.05.007
[27]	Abramson DH, Ji XD, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds[J]. Br J Ophthalmol, 2019, 103(4): 488-93. doi: 10.1136/bjophthalmol-2018-312037
[28]	Silverman RH. Focused ultrasound in ophthalmology[J]. Clin Ophthalmol, 2016, 10: 1865-75. doi: 10.2147/OPTH.S99535
[29]	Kadakia A, Zhang JH, Yao XC, et al. Ultrasound in ocular oncology: technical advances, clinical applications, and limitations [J]. Exp Biol Med (Maywood), 2023, 248(5): 371-9. doi: 10.1177/15353702231169539
[30]	Koch KR, Mor JM, Avgitidou G, et al. Klinisch-echographische diagnostik Bei iristumoren[J]. Der Ophthalmol, 2019, 116(4): 313-23. doi: 10.1007/s00347-019-0861-y
[31]	Ferreira TA, Saraiva P, Genders SW, et al. CT and MR imaging of orbital inflammation[J]. Neuroradiology, 2018, 60(12): 1253-66. doi: 10.1007/s00234-018-2103-4
[32]	Venkateswaran N, Sripawadkul W, Karp CL. The role of imaging technologies for ocular surface tumors[J]. Curr Opin Ophthalmol, 2021, 32(4): 369-78. doi: 10.1097/ICU.0000000000000771
[33]	Mirzayev I, Gündüz AK, Aydın Ellialtıoğlu P, et al. Clinical applications of anterior segment swept-source optical coherence tomography: a systematic review[J]. Photodiagn Photodyn Ther, 2023, 42: 103334. doi: 10.1016/j.pdpdt.2023.103334
[34]	Pellegrini M, Staurenghi G, Preziosa C. Clinical applications of optical coherence tomography angiography in ocular oncology: pearls and pitfalls[J]. Ocul Oncol Pathol, 2022, 8(2): 79-87. doi: 10.1159/000520951
[35]	Greig EC, Laver NV, Mendonca LSM, et al. Swept-source optical coherence tomography angiography in small choroidal melanomas and choroidal nevi[J]. Retina Phila Pa, 2021, 41(6): 1182-92. doi: 10.1097/IAE.0000000000003053
[36]	Jaarsma-Coes MG, Ferreira TA, Marinkovic M, et al. Comparison of magnetic resonance imaging-based and conventional measurements for proton beam therapy of uveal melanoma[J]. Ophthalmol Retina, 2023, 7(2): 178-88. doi: 10.1016/j.oret.2022.06.019
[37]	Klaassen L, Jaarsma-Coes MG, Verbist BM, et al. Automatic Three-Dimensional Magnetic Resonance-based measurements of tumour prominence and basal diameter for treatment planning of uveal melanoma[J]. Phys Imag Radiat Oncol, 2022, 24: 102-10. doi: 10.1016/j.phro.2022.11.001
[38]	Fiedorowicz M, Wełniak-Kamińska M, Świątkiewicz M, et al. Changes of ocular dimensions as a marker of disease progression in a murine model of pigmentary glaucoma[J]. Front Pharmacol, 2020, 11: 573238. doi: 10.3389/fphar.2020.573238
[39]	Ferreira Teresa A, JaarsmaCoes Myriam G, Marina M, et al. MR imaging characteristics of uveal melanoma with histopathological validation[J]. Neuroradiology, 2021, 64(1): 171-84.
[40]	Hirunpat P, Sanghan N, Hirunpat S. White matter: a good reference for the signal intensity evaluation in magnetic resonance imaging for the diagnosis of uveal melanoma[J]. Neuroradiol J, 2021, 34 (2): 113-9. doi: 10.1177/1971400920973407
[41]	Rantala ES, Hernberg MM, Piperno-Neumann S, et al. Metastatic uveal melanoma: the final frontier[J]. Prog Retin Eye Res, 2022, 90: 101041. doi: 10.1016/j.preteyeres.2022.101041
[42]	Murad S, Ahmed I, Ali H, et al. Diagnostic accuracy of B-scan in predicting retinoblastoma in children, taking Magnetic Resonance Imaging of orbits as gold standard[J]. J Pak Med Assoc, 2020: 1-7.
[43]	Jansen RW, van der Heide S, Cardoen L, et al. Magnetic resonance imaging can reliably differentiate optic nerve inflammation from tumor invasion in retinoblastoma with orbital cellulitis[J]. Ophthalmology, 2022, 129(11): 1275-86. doi: 10.1016/j.ophtha.2022.06.013
[44]	Kalemaki M, Karantanas A, Exarchos D, et al. PET/CT and PET/ MRI in ophthalmic oncology (review)[J]. Int J Oncol, 2020, 56(2): 417-29.
[45]	Marko M, Lesko P, Jurenova D, et al. Importance of PET/CT examination in patients with malignant uveal melanoma[J]. Czech Slovak Ophthalmol, 2020, 76(1): 37-44.
[46]	Wang WF, Ni XC, Tang TC, et al. The role of ¹⁸F-FDG PET/CT in diagnosis and treatment evaluation for ocular adnexal mucosaassociated lymphoid tissue lymphoma[J]. Br J Radiol, 2022, 95 (1130): 20210635. doi: 10.1259/bjr.20210635
[47]	Yeung AM, Wells JR, Grossniklaus HE. Secondary ocular malignancies: a review[J]. Clin Exp Ophthalmol, 2021, 49(2): 161-8. doi: 10.1111/ceo.13889
[48]	Li XY, Wang LX, Zhang L, et al. Application of multimodal and molecular imaging techniques in the detection of choroidal melanomas[J]. Front Oncol, 2021, 10: 617868. doi: 10.3389/fonc.2020.617868
[49]	Liu HJ, Liu YH, Chen Y, et al. Detection of parotid metastasis from retinoblastoma by ¹⁸F-FDG PET/CT scan[J]. Rev Esp De Med Nucl E Imagen Mol Engl Ed, 2022, 41(Suppl 1): S8-9.
[50]	Yan B, Fu T, Liu YM, et al. ^99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma[J]. Medicine, 2018, 97(40): e12441. doi: 10.1097/MD.0000000000012441
[51]	Harada N, Kondo K, Terazono S, et al. The diagnostic value of 123I-IMP SPECT in ocular adnexal lymphoma[J]. Int Ophthalmol, 2022, 42(4): 1205-12. doi: 10.1007/s10792-021-02105-4
[52]	Yamazaki K, Nishii R, Maeda T, et al. Assessment of SPECT-CT fusion images and semi-quantitative evaluation using SUV in ^{^123}I-IMP SPECT in patients with choroidal melanoma[J]. Ann Nucl Med, 2020, 34(11): 864-72. doi: 10.1007/s12149-020-01517-z
[53]	Salvatori M, Rizzo A, Rovera G, et al. Radiation dose in nuclear medicine: the hybrid imaging[J]. La Radiol Med, 2019, 124(8): 768-76. doi: 10.1007/s11547-019-00989-y
[54]	Habibalahi A, Bala C, Allende A, et al. Novel automated non invasive detection of ocular surface squamous neoplasia using multispectral autofluorescence imaging[J]. Ocul Surf, 2019, 17(3): 540-50. doi: 10.1016/j.jtos.2019.03.003
[55]	Bindewald-Wittich A, Holz FG, Ach T, et al. Fundus autofluorescence imaging in patients with choroidal melanoma[J]. Cancers, 2022, 14(7): 1809. doi: 10.3390/cancers14071809
[56]	Geiger F, Said S, Bajka A, et al. Assessing choroidal nevi, melanomas and indeterminate melanocytic lesions using multimodal imaging-a retrospective chart review[J]. Curr Oncol, 2022, 29(2): 1018-28. doi: 10.3390/curroncol29020087

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 114
HTML全文浏览量: 54
PDF下载量: 8
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

分子影像技术应用于眼科肿瘤的研究进展

doi: 10.12122/j.issn.1674-4500.2023.06.32

作者简介:
王玲，在读硕士研究生，E-mail: lingwang@stu.njmu.edu.cn

通讯作者:
王柯，博士，研究员，E-mail: wangke@jsinm.org

计量

Research progress of molecular imaging technology for ocular tumor

计量

目录

留言板

分子影像技术应用于眼科肿瘤的研究进展

doi: 10.12122/j.issn.1674-4500.2023.06.32

作者简介: 王玲，在读硕士研究生，E-mail: lingwang@stu.njmu.edu.cn

通讯作者: 王柯，博士，研究员，E-mail: wangke@jsinm.org

计量

出版历程

Research progress of molecular imaging technology for ocular tumor

计量

出版历程

目录

作者简介:
王玲，在读硕士研究生，E-mail: lingwang@stu.njmu.edu.cn

通讯作者:
王柯，博士，研究员，E-mail: wangke@jsinm.org